The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMXC.L Regulatory News (MXC)

  • There is currently no data for MXC

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

SPP – Extension of Closing Date

15 Aug 2023 07:29

RNS Number : 3536J
MGC Pharmaceuticals Limited
15 August 2023
 

 

SPP - Extension of Closing Date

15 August 2023

ASX Code: MXC

LSE Code: MXC

 

 

MGC Pharmaceuticals Ltd (MGC Pharma, MGC or the Company) refers to its prospectus lodged with ASIC and released on the ASX on 3 August 2023 in relation to its security purchase plan (SPP), as first announced to the ASX on 1 August 2023 (Prospectus).

Defined terms used in this announcement have the meaning given to them in the Prospectus, unless specified otherwise.

The Company wishes to advise that the Closing Date for the SPP has been extended from 5:00pm (AWST) on Friday, 18 August 2023 until 5:00pm (AWST) on Friday, 25 August 2023. The Company has also released an updated Appendix 3B reflecting the extended Closing Date.

The SPP timetable has been revised as follows:

Action

Date

Record Date for SPP

5:00pm (AWST) on 31 July 2023

Announcement of SPP and lodgment of Appendix 3B with ASX

1 August 2023

Lodgment of Prospectus for issue of SPP Securities with ASIC and ASX

3 August 2023

Opening date of the SPP Offer under the Prospectus

4 August 2023

Closing Date of the SPP Offer under the Prospectus**

25 August 2023

Announcement of the results of the SPP

29 August 2023

Issue of SPP Shares and lodgement of Appendix 2A for the SPP Shares with ASX

1 September 2023

General Meeting to approve the issuance of the SPP Options

5 September 2023

Issue of SPP Options and lodgement of forms for the SPP Options with ASX

6 September 2023

\* The above dates are indicative only and may change without prior notice.

**Subscribers under the SPP Offer should ensure that they have lodged their SPP Application Form by this date.

Further details of the SPP Offer, including details on how to apply under the SPP Offer and key risks associated with an investment in the Company are set out in the Prospectus. Applications for new Shares and free attaching Options (subject to Shareholder approval at the upcoming general meeting) under the SPP Offer may only be made by completing the Application Form accompanying the Prospectus in accordance with the instructions outlined on the Application Form. Shareholders eligible to participate in the SPP Offer should read the Prospectus carefully and consult their professional advisers as necessary.

 

-Ends-

 

Authorised for release by the board of directors, for further information please contact:

MGC Pharmaceuticals Ltd

Roby Zomer

CEO & Managing Director

+61 8 6555 2950

info@mgcpharma.co.uk

MGC Pharmaceuticals Ltd

Rowan Harland

Company Secretary

+61 8 6555 2950

info@mgcpharma.co.uk

UK IR/PR Advisers 

IFC Advisory

Graham Herring / Tim Metcalfe / Zach Cohen

+44 203 934 6630

mgcpharma@investor-focus.co.uk

UK Brokers

Oberon Capital

Aimee McCusker / Adam Pollock

+44 203 179 5300

aimeemccusker@oberoninvestments.com adampollock@oberoninvestments.com 

 

About MGC Pharma

MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based pharmaceutical company, focused on developing and supplying accessible and ethically produced plant derived medicines, combining in-house research with innovative technologies, with the goal of finding or producing treatments to for unmet medical conditions.

The Company's founders and executives are key figures in the global pharmaceuticals industry and the core business strategy is to develop and supply high quality plant derived medicines for the growing demand in the medical markets in Europe, North America and Australasia.

 

MGC Pharma has a robust development pipeline targeting two widespread medical conditions and has further products under development. 

 

MGC Pharma has partnered with renowned institutions and academia to optimise the development of targeted plant derived medicines, to be produced in the Company's EU-GMP Certified manufacturing facilities. 

 

MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market.

 

Follow us through our social media channels:

LinkedIn: MGC Pharmaceuticals Ltd.

Twitter: @MGC_Pharma

Facebook: @mgcpharmaceuticals

Instagram: @mgc_pharma

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCUVUNROOUWARR
Date   Source Headline
2nd Sep 20219:05 amRNSSecond Price Monitoring Extn
2nd Sep 20219:00 amRNSPrice Monitoring Extension
2nd Sep 20217:00 amRNSCimetrA import approval granted in India
1st Sep 20217:00 amRNSPreliminary Financial Report for 30 June 2021
31st Aug 20217:00 amRNSProposed Issue of Securities and Appendix 3B
27th Aug 20219:00 amRNSHolder Update - MXCOE Listed Options
26th Aug 20219:05 amRNSSecond Price Monitoring Extn
26th Aug 20219:00 amRNSPrice Monitoring Extension
26th Aug 20217:10 amRNSMGC Pharma executes US$24m agreement with US firm
12th Aug 20211:21 pmRNSResults of General Meeting
6th Aug 20218:47 amRNSGeneral Meeting Information and Webinar
3rd Aug 20217:00 amRNSExpiry of Share Options
26th Jul 20217:00 amRNSQuarterly Results
16th Jul 20217:56 amRNSAmendment to Expiry of Share Options
15th Jul 20217:17 amRNSCannabinoid Patent Application Submitted
13th Jul 202110:52 amRNSExpiry of Share Options
13th Jul 20219:38 amRNSIssue of Shares and Cleansing Statement
12th Jul 20217:00 amRNSPhase III CimetrA™ Clinical Trial Commences
9th Jul 20219:16 amRNSCleansing Notice and Appendix 2A
9th Jul 20217:00 amRNSNotice of GM
15th Jun 20217:00 amRNSCannEpil - Primary Care Reimbursement in Ireland
9th Jun 20217:24 amRNSAppointment of Company Secretary
25th May 20217:00 amRNS2021 Clinical Trials Program Update
17th May 20217:58 amRNSCimetrA Patent Submitted to European IP Office
14th May 20217:59 amRNSAppendix 3G
14th May 20217:50 amRNSAppendix 2A - Issue of Shares
7th May 20217:27 amRNSResearch Update - ArtemiC
6th May 20212:00 pmRNSPrice Monitoring Extension
6th May 20217:31 amRNSASX Trading Halt
4th May 20217:00 amRNSNew ArtemiC Order Received From Swiss PharmaCan AG
28th Apr 20217:00 amRNSApplication to Health Canada for ArtemiC Approval
27th Apr 20217:00 amRNSQuarterly Results
22nd Apr 20217:00 amRNSAcquisition of MediCaNL
21st Apr 202112:36 pmRNSIssue of Equity
9th Apr 20217:00 amRNSInvestor Presentation
8th Apr 202111:00 amRNSCorporate Update
7th Apr 20217:08 amRNSArtemiC Rescue First Delivery and March Revenue
31st Mar 202112:54 pmRNSGM Statement
24th Mar 20219:03 amRNSAppendix 2A - Issue of Shares
22nd Mar 20217:30 amRNSPhase III Clinical Trial of CimetrA Approved
19th Mar 20217:00 amRNSNotice of GM
9th Mar 20218:19 amRNSAppendix 2A - Issue of Shares
9th Mar 20217:00 amRNSDirector/PDMR Shareholding
2nd Mar 20217:00 amRNSIncreased initial supply agreement for ArtemiC
26th Feb 20217:17 amRNSNotice of GM
26th Feb 20217:00 amRNSHalf-year Report
25th Feb 20219:05 amRNSSecond Price Monitoring Extn
25th Feb 20219:00 amRNSPrice Monitoring Extension
19th Feb 20214:41 pmRNSSecond Price Monitoring Extn
19th Feb 20214:36 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.